The global guillain-barre syndrome diagnostics market size is expected to reach USD 169.9 million by 2030, registering a CAGR of 2.8% from 2025 to 2030, according to a new report by Grand View Research, Inc. driven by several key factors. A significant contributor is the increasing incidence of Guillain-Barre syndrome (GBS), particularly in regions with high rates of infectious diseases. Infections such as respiratory or gastrointestinal illnesses often precede GBS, leading to a heightened demand for effective diagnostic tools. For instance, a study from the University of Minnesota in October 2023 highlighted that 67% of GBS cases were preceded by such infections, underscoring the need for timely diagnosis.
Advancements in diagnostic techniques have also played a crucial role in market expansion. Innovations in electromyography (EMG) and nerve conduction studies have enhanced the accuracy and speed of GBS diagnosis. These technological improvements enable healthcare professionals to detect the syndrome earlier, facilitating prompt intervention and better patient outcomes. The integration of advanced diagnostic tools in clinical settings has become increasingly prevalent, reflecting a commitment to improving patient care.
The growing awareness of GBS among healthcare providers and the general population has further propelled the diagnostics market. Educational initiatives and increased information dissemination have led to earlier recognition of symptoms and subsequent diagnostic testing. This heightened awareness ensures that patients receive timely and appropriate care, reducing the risk of severe complications associated with delayed diagnosis. Consequently, the demand for diagnostic services has risen, contributing to market growth.
The expanding geriatric population has influenced the market for GBS diagnostics. Older individuals are more susceptible to infections that can trigger GBS, necessitating effective diagnostic measures. According to the World Health Organization's 2021 forecast, by 2030, one in six individuals worldwide will be over 60, with their numbers expected to grow from 1 billion in 2020 to 2.1 billion by 2050. This demographic shift underscores the importance of accessible and accurate diagnostic tools to manage the anticipated increase in GBS cases among the elderly.
Key players in the market are implementing strategic initiatives such as geographical expansion, collaborations, partnerships, and joint ventures to strengthen their market presence.
Request a free sample copy or view report summary: Guillain-Barre Syndrome Diagnostics Market Report
The test segment of the market includes lumbar puncture, electromyography, nerve conduction studies, and others. The lumbar puncture segment led the market in 2024, accounting for the largest revenue share of 45.1%, and is expected to experience the fastest compound annual growth rate (CAGR) of 3.0% during the forecast period, driven by its essential role in confirming GBS diagnosis.
The end-use segment comprises hospitals & clinics, and diagnostic laboratories. In 2024, the hospitals & clinics segment led the market, capturing a revenue share of 63.0%, driving significant growth through the integration of advanced diagnostic tools and improved patient management protocols.
Asia Pacific dominated the global market with a revenue share of 41.8% in 2024. Factors such as rising awareness, improving healthcare infrastructure, and increasing diagnostic rates are driving market expansion.
Grand View Research has segmented the global GBS diagnostics market based on the test, end-use, and region:
GBS Diagnostics Test Outlook (Revenue, USD Million, 2018 - 2030)
Lumbar Puncture
Nerve Conduction
Electromyography
Other
GBS Diagnostics End-use Outlook (Revenue, USD Million, 2018 - 2030)
Hospitals and Clinics
Diagnostic Laboratories
Others
GBS Diagnostics Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Mexico
Europe
UK
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
Australia
South Korea
Thailand
Latin America
Brazil
Argentina
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
List of Key Players in the GBS Diagnostics Market
Cadwell Industries, Inc
Natus Medical Incorporated
Nihon Kohden Corporation
Medtronic plc
Bionen Medical Devices
Deymed Diagnostic
Neurosoft
Alpine Biomed
EMS Biomedical
Rochester Electro-Medical, Inc.
"The quality of research they have done for us has been excellent..."